Michael R Barbachyn


Michael Barbachyn

Education

  • B.A., Chemistry, Calvin College, 1979
  • Ph.D., Organic Chemistry, Wayne State University, 1983
  • NIH Postdoctoral Fellow, Yale University, 1983-1985

Thesis: β-Hydroxysulfoximine-Directed Cyclopropanations and Osmylations
Advisor: Dr. Carl R. Johnson

 

Professional experience

  • Part-time/Adjunct Professor of Chemistry - Calvin University, 2020-present
  • Brummel Professor of Organic Chemistry - Calvin University, 2012-2020
  • Director, Infection Discovery - AstraZeneca, Waltham, MA, 2007-2012
  • Director, Antibacterial Chemistry - Pfizer, Ann Arbor, MI, 2003-2007
  • Associate Director, Medicinal Chemistry - Pharmacia, Kalamazoo, MI, 2000-2003
  • Group Leader, Hepatitis C Project - Bristol-Myers Squibb, Wallingford, CT, 1998-1999
  • Scientist I-IV - The Upjohn Company and Pharmacia and Upjohn, Kalamazoo, MI, 1985-1998

Biography

Mike Barbachyn initiated his 27-year career in the pharmaceutical industry by joining The Upjohn Company in 1985 and conducting medicinal chemistry research in the antibacterial agent area. His early efforts were focused on monocyclic beta-lactam antibiotics, exemplified by the monobactam aztreonam, and culminated in the identification of a pre-clinical drug candidate, U-78608, a potent antipseudomonal monocarbam incorporating a siderophore-mimicking side chain. He continued to work on a variety of antibacterial agent classes, including the fluoroquinolones and oxazolidinones. A number of compounds from both of these classes were ultimately identified as pre-clinical drug candidates, with several oxazolidinone analogs eventually progressing to human clinical trials. For example, he co-invented the clinical oxazolidinones eperezolid (PNU-100592, the first oxazolidinone to successfully complete Phase 1 trials), linezolid (PNU-100766, approved by the FDA and marketed in 2000 as Zyvox™), PNU-141659 (Phase 1), PNU-288034 (Phase 1), and sutezolid (PNU-100480, currently in Phase 2 clinical trials for TB therapy). Over the course of his industrial career, he also engaged in research involving a number of other novel pre-clinical classes of antibacterials, arising from either target-based or phenotypic screening. During the course of his stay in Kalamazoo, MI, his employer’s name changed repeatedly because of a series of mergers, first to Pharmacia & Upjohn, then Pharmacia, and finally Pfizer. In 2003, he moved to the Pfizer site in Ann Arbor, MI, where he continued to actively work in the antibacterial area for another 4 years. Upon Pfizer’s closure of the Ann Arbor research site, he joined the infection group at AstraZeneca, in Waltham, MA, where his focus was again on anti-infective discovery and development over a 5-year period. 

In 2012, he formed his own consulting practice, Barbachyn Consulting, LLC, and also joined the faculty of the Department of Chemistry and Biochemistry at Calvin College, (now Calvin University) in Grand Rapids, MI, where he was the Brummel Chair in Organic Chemistry through August 2020. His research efforts at Calvin have been and are currently aimed at developing new synthetic methodology that can be applied to the preparation of novel anti-infective agents. He remains active in the anti-infective community, regularly serving on NIH and CARB-X Study Sections and reviewing manuscripts submitted for publication. Mike also serves on the Scientific Advisory Boards of several antibacterial biotech companies, including Forge Therapeutics, Curza, Linnaeus Bioscience, and Bactria.

Research and scholarship

  • Development of novel organic synthetic methodology
  • Identification of unique bioisosteres with applicability in pharmaceutical agents
  • Design and preparation of novel anti-infective agents with activity against multidrug-resistant pathogens

Publications

Undergraduate student names appear in bold

Bell, A.; Boomsma, A.; Flikweert, N.; Hohlman, R.; Zhang, S.; Blankespoor, R.; Biros, S.; Staples, R.; Brickner, S.; Barbachyn, M. "The Synthesis of Functionalized 3-Aryl- and 3-Heteroaryloxazolidin-2-ones and Tetrahydro-3-Aryl-1,3-oxazin-2-ones via the Iodocyclocarbamation Reaction.  Access to Privileged Chemical Structures and Scope and Limitations of the Method."  Journal of Organic Chemistry, 85, 6323-6337.https://doi.org/10.1021/acs.joc.9b03400. 2020. 

Barbachyn, M. R. In Topics in Medicinal Chemistry; Fisher, J.; Mobashery, S.; Miller, M. Eds.; Springer. doi:10.1007/7355_2017_15, url: https://doi.org/10.1007/7355_2017_15. “The Oxazolidinones.” 22 April 2017.

Anderson, D. J.; Banitt, L. S.; Barbachyn, M. R.; et al. manuscript submitted to Antimicrobial Agents and Chemotherapy,  “Structure-Activity Relationships of Quinoline Pyrimidine Trione (QPT) Antibacterials.” 2013. 

Barbachyn, M. R.; In Antibiotic Discovery and Development; Dougherty, T. J.; Pucci, M. J.; Eds.; Springer, 2011; Volume 1, Chapter 8. “Oxazolidinone Antibacterial Agents.”

Shaw, K.; Barbachyn, M. R.; Annals of the New York Academy of Sciences, 1241, 48-70.  “The Oxazolidinones: Past, Present and Future.” 2011. 

Starr, J. T.; Sciotti, R. J.; Hanna, D. L.; Huband, M. D.; Mullins, L. M.; Cai, H.; Gage, J. W.; Lockard, M.; Rauckhorst, M. R.; Owen, R. M.; Lall, M. S.; Tomilo, M.; Chen, H.; McCurdy, S. P.; Barbachyn, M. R.; Bioorganic & Medicinal Chemistry Letters, 19, 5302-5306.  “5-(2-Pyrimidinyl)-imidazo[1,2-a]pyridines are Antibacterial Agents Targeting the ATPase Domains of DNA GyrAse and Topoisomerase IV.” 2009. 

Ruble, J. C.; Hurd, A. R.; Johnson, T. A.; Sherry, D. A.; Barbachyn, M. R.; Toogood, P. L.; Bundy, G. L.; Graber, D. R.; Kamilar, G. M.  Journal of the American Chemical Society, 130, 3991-3997.  “Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates.” 2009. 

Barbachyn, M. R.; “Recent Advances in the Discovery of Hybrid Antibacterial Agents.” In Annual Reports in Medicinal Chemistry, Vol. 43; Macor, J. E., Primeau, J. Eds.; Elsevier:  London, UK, pp 281-290. 2008. 

Miller, A. A.; Bundy, G. L.; Mott, J. E.; Skepner, J. E.; Boyle, T. P.; Harris, D. W.; Hromockyj, Marotti, K. R.; Zurenko, G. E.; Munzner, J. B.; Sweeney, M. T.; Bammert, G. F.; Hamel, J. C.; Ford, C. W.; Zhong, W.-Z.; Graber, D. R.; Martin, G. E.; Han, F.; Dolak, L. A.; Seest, E. P.; Ruble, J. C.; Kamilar, G. M.; Palmer, J. R.; Banitt, L. S.; Hurd, A. R.; Barbachyn, M. R.;  Antimicrobial Agents and Chemotherapy, 52, 2806-2812.  “Discovery and Characterization of QPT-1, the Progenitor of a New Class of Bacterial Topoisomerase Inhibitors.” 2008. 

Brickner, S. J.; Barbachyn, M. R.; Hutchinson, D. K.; Manninen, P. R.; Journal of Medicinal Chemistry, 51, 1981-1990.  “Linezolid (ZYVOXâ), the First Member of a Completely New Class of Antibacterial Agents for Treatment of Serious Gram-Positive Infections.” 2008. 

Poel, T.-J.; Thomas, R. C.; Adams, W. J.; Aristoff, P. A.; Barbachyn, M. R.; Boyer, F. E.; Brieland, J.; Brideau, R.; Brodfuehrer, J.; Brown, A. P.; Choy, A. L.; Dermyer, M.; Dority, M.; Ford, C. W.; Gadwood, R. C.; Hanna, D.; Hongliang, C.; Huband, M. D.; Huber, C.; Kelly, R.; Kim, J.-Y.; Martin, J. P., Jr.; Pagano, P. J.; Ross, D.; Skerlos, L.; Sulvik, M. A.; Zhu, T.; Zurenko, G. E.; Prasad, J. V. N.  Journal of Medicinal Chemistry, 50, 5886-5889.  “Antibacterial Oxazolidinones Possessing a Novel C-5 Side Chain.  (5R)-trans-3-[3-Fluoro-4-(1-oxotetrahydrothiopyran-4-yl)phenyl]-2-oxooxazolidine-5-carboxylic Acid Amide (PF-00422602), a New Lead Compound.” 2007.

Perrault, W. R.; Pearlman, B. A.; Godrej, D. B.; Jeganathan, A.; Yamagata, K.; Chen, J. J.; Lu, C. V.; Herrinton, P. M.; Gadwood, R. C.; Chan, L.; Dorow, R. L.; Lyster, M. A.; Maloney, M. T.; Moeslein, J. A.; Greene, M. L.; Barbachyn, M. R.  Organic Process Research and Development, 7, 533-546.  "The Synthesis of N-aryl-5(S)-aminomethyl-2-oxazolidinone Antibacterials and Derivatives in one step from Aryl Carbamates." 2003. 

Ciske, F. L.; Barbachyn, M. R.; Genin, M. J.; Grega, K. C.; Lee, C. S.; Dolak, L. A.; Seest, E. P.; Watt, W.; Adams, W. J.; Friis, J. M.; Ford, C. W.; Zurenko, G. E.; Bioorganic & Medicinal Chemistry Letters, 13, 4235-4239.  "The Potentiating Effect of Remote Chirality on the Antibacterial Activity of Indolinyl, Tetrahydroquinolyl and Dihydrobenzoxazinyl Oxazolidinones." 2003. 

Gordeev, M. F.; Hackbarth, C.; Barbachyn,  M. R.; Banitt, L. S.; Gage, J. R.; Luehr, G. W.; Gomez, M.; Trias, J.; Morin, S. E.; Zurenko, G. E.; White, R. J.; Patel, D. V.; Bioorganic & Medicinal Chemistry Letters, 13, 4213-4216.  "Novel Oxazolidinone-Quinolone Hybrid Antimicrobials." 2003.

Barbachyn, M. R.; Cleek, G. J.; Dolak, L. A.; Garmon, S. A.; Morris, J.; Seest, E. P.; Thomas, R. C.; Toops, D. S.; Watt, W.; Wishka, D. G.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H.; Adams, W. J.; Friis, J. M.; Slatter, J. G.; Sams, J. P.; Oien, N. L.; Zaya, M. J.; Wienkers, L. C.; Wynalda, M. A.;  Journal of Medicinal Chemistry, 46, 284-302.  “The Identification of Phenylisoxazolines as Novel and Viable Antibacterial Agents Active Against Gram-Positive Pathogens.” 2003. 

Barbachyn, M. R.; Ford, C. W.;  Angewandte Chemie International Edition, 42, 2010-23.  "Oxazolidinone Structure-Activity Relationships Leading to Linezolid." 2003. 

Ford, C. W.; Zurenko, G. E.; Barbachyn, M. R.  Current Drug Targets, 1, 19-36.  “The Discovery of Linezolid, the First Oxazolidinone Antibacterial Agent.” 2001. 

Lee, C.-S.; Allwine, D. A.; Barbachyn, M. R.; Dolak, L. A.; Grega, K. C.; Ford, C. W.; Jensen, R. M.; Seest, E. P.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H.; Genin, M. J.; Bioorganics & Medicinal Chemistry, 9, 3243-3253. “Carbon-Carbon-Linked (Pyrazolylphenyl)oxazolidinones with Antibacterial Activity Against Multiple Drug Resistant Gram-Positive and Fastidious Gram-Negative Bacteria.” 2001. 

Genin, M. J.; Allwine, D. A.; Anderson, D. J.; Barbachyn, M. R.; Emmert, E.; Garmon, S. A.; Graber, D. R.; Grega, K. C.; Hester, J. B.; Hutchinson, D. K.; Morris, J.; Reischer, R. J.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H.; Journal of Medicinal Chemistry, 43, 953.  “Substituent Effects on the Antibacterial Activity of Nitrogen-Carbon Linked Azolylphenyl Oxazolidinones with Expanded Activity Against the Fastidious Gram-Negative Organisms Haemophilus influenzae and Moraxella catarrhalis.” 2000.

Ford, C. W.; Hamel, J.; Stapert, D.; Moerman, J.; Hutchinson, D.; Barbachyn, M.; Zurenko, G.; Infections in Medicine, 16, 43.  “Oxazolidinones: A New Class of Antimicrobials.” 1999. 

Barbachyn, M. R.; Brickner, S. J.; Gadwood, R. C.; Garmon, S. A.; Grega, K. C.; Hutchinson, D. K.; Munesada, K.; Reischer, R. J.; Taniguchi, M.; Thomasco, L. M.; Toops, D. S.; Yamada, H.; Ford, C. W.; Zurenko, G. E.;  Advances in Experimental Medicine and Biology, 456, 219-38.  “Design, synthesis, and evaluation of novel oxazolidinone antibacterial agents active against multidrug-resistant bacteria.” 1998.

Barbachyn, M. R.; Brickner, S. J.; Gadwood, R. C.; Garmon, S. A.; Hutchinson, D. K.; Grega, K. C.; Munesada, K.; Reischer, R. J.; Taniguchi, M.; Thomasco, L. M.; Toops, D. S.; Yamada, H.; Ford, C. W.; Zurenko, G. E.; In Resolving the Antibiotic Paradox; Rosen, B. P., Mobashery, S., Eds.; Kluwer Academic/Plenum: New York, Vol. 456, Chapter 12. “Design, Synthesis, and Evaluation of Novel Oxazolidinone Antibacterial Agents Active Against Multidrug-Resistant Bacteria.” 1998.

Tucker, J. A.; Allwine, D. A.; Grega, K. C.; Barbachyn, M. R.; Klock, J. L.; Adamski, J. L.; Brickner, S. J.; Hutchinson, D. K.; Ford, C. W.; Zurenko, G. E.; Conradi, R. A.; Burton, P. S.; Jensen, R. M.; Journal of Medicinal Chemistry, 41, 3727.  “Piperazinyl Oxazolidinone Antibacterial Agents Containing a Pyridine, Diazine, or Triazine Heteroaromatic Ring.” 1998.

Ford, C. W.; Hamel, J. C.; Stapert, D.; Moerman, J. K.; Hutchinson, D. K.; Barbachyn, M. R.; Zurenko, G. E.; Trends in Microbiology: Virulence, Infection and Pathogenesis, 5, 196.  “Oxazolidinones: New Antibacterial Agents.” 1997.

Zurenko, G. E.; Ford, C. W.; Hutchinson, D. K.; Brickner, S. J.; Barbachyn, M. R. Expert Opinion on Investigational Drugs, 6, 151.  “Oxazolidinone Antibacterial Agents; Development of the Clinical Candidates Eperezolid and Linezolid.” 1997.

Barbachyn, M. R.; Brickner, S. J.; Cleek, G. J.; Gadwood, R. C.; Grega, K. C.; Hendges, S. K.; Hutchinson, D. K.; Manninen, P. R.; Munesada, K.; Thomas, R. C.; Thomasco, L. M.; Toops, D. S.; Ulanowicz, D. A.  “Design and Synthesis of Novel Oxazolidinones Active Against Multidrug-Resistant Bacteria.” In Anti-Infectives: Recent Advances in Chemistry and Structure-Activity Relationships; Bentley, P. H., O'Hanlon, P. J., Eds.; The Royal Society of Chemistry:  Cambridge, UK, pp 15-26. 1997.

Ford, C. W.; Hamel, J. C.; Wilson, D. M.; Moerman, J. K.; Stapert, D.; Yancey, R. J., Jr.; Hutchinson, D. K.; Barbachyn, M. R.; Brickner, S. J.; Antimicrobial Agents and Chemotherapy, 40, 1508.  “In Vivo Activity of U-100592 and U-100766, Novel Oxazolidinone Antimicrobial Agents, Against Experimental Bacterial Infections.” 1996.

Zurenko, G. E.; Yagi, B. H.; Schaadt, R. D.; Allison, J. W.; Kilburn, J. O.; Glickman, S. E.; Hutchinson, D. K.; Barbachyn, M. R.; Brickner, S. J.; Antimicrobial Agents and Chemotherapy, 40, 839.  “In Vitro activity of U-100592 and U-100766, Novel Oxazolidinone Antibacterial Agents.” 1996.

Barbachyn, M. R.; Toops, D. S.; Grega, K. C.; Hendges, S. K.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H.; Buysse, J. M.; Demyan, W. F.; Kilburn, J. O.; Glickman, S. E.; Bioorganic & Medicinal Chemistry Letters, 6, 1009.  “Synthesis and Antibacterial Activity of New Tropone-Substituted Phenyloxazolidinones.  2.  Modification of the Phenyl Ring - the Potentiating Effect of Fluorine Substitution on In Vivo Activity.” 1996.

Barbachyn, M. R.; Toops, D. S.; Ulanowicz, D. A.; Grega, K. C.; Brickner, S. J.; Ford, C. W.; Zurenko, G. E.; Hamel, J. C.; Schaadt, R. D.; Stapert, D.; Yagi, B. H.; Buysse, J. M.; Demyan, W. F.; Kilburn, J. O.; Glickman, S. E.; Bioorganic & Medicinal Chemistry Letters, 6, 1003.  “Synthesis and Antibacterial Activity of New Tropone-Substituted Phenyloxazolidinones.  1.  Identification of Leads and Importance of the Tropone Substitution Pattern.” 1996. 

Barbachyn, M. R.; Hutchinson, D. K.; Brickner, S. J.; Cynamon, M. H.; Kilburn, J. O.; Klemens, S. P.; Glickman, S. E.; Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G. E.; Journal of Medicinal Chemistry, 39, 680.  “Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity.” 1996.

Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D. A.; Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G. E.; Journal of Medicinal Chemistry, 39, 673.  “Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections.” 1996.

Grega, K. C.; Barbachyn, M. R.; Brickner, S. J.; Mizsak, S. A.; Journal of Organic Chemistry, 60, 5255.  “Regiospecific Metalation of Fluoroanilines: an Application to the Synthesis of Fluorinated Oxazolidinone Antibacterial Agents.” 1995.

Barbachyn, M. R. “Cerium (III) Acetate-Boron Trifluoride Etherate.”  In Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A., Ed.; John Wiley & Sons, Inc.: New York, 1994.

Toops, D. S.; Barbachyn, M. R.; Journal of Organic Chemistry, 58, 6505.  “Efficient Synthesis of 1-(Trialkylstannyl)- and 1-(Triarylstannyl) bicyclo[1.1.1] pentanes.” 1993.

Barbachyn, M. R.; Hutchinson, D. K.; Toops, D. S.; Reid, R. J.; Zurenko, G. E.; Yagi, B. H.; Schaadt, R. D.; Allison, J. W.; Bioorganic & Medicinal Chemistry Letters, 3, 671. “U-87947E, a Potent Quinolone Antibacterial Agent Incorporating a Bicyclo[1.1.1]pent-1-yl (BCP) Subunit.” 1993.

Barbachyn, M. R.; Tuominen, T. C.; Journal of Antibiotics, 43, 1199.  “Synthesis and Structure-Activity Relationships of Monocarbams Leading to U-78608.” 1990.

Danishefsky, S. J.; DeNinno, S. L.; Chen, S.-H.; Boisvert, L.; Barbachyn, M. R.; Journal of the American Chemical Society, 111, 5810.  “Fully Synthetic Stereoselective Routes to the Differentially Protected Subunits of the Tunicamycins.” 1989.

Danishefsky, S. J.; Barbachyn, M. R., Journal of the American Chemical Society, 107, 7761.  “A Fully Synthetic Route to Tunicaminyluracil.” 1985.

Johnson, C. R.; Barbachyn, M. R.; Meanwell, N. A.; Stark, C. J., Jr.; Zeller, J. R.; Phosphorous and Sulfur, 24, 151-163.  “Utilization of Sulfoximines in the Synthesis of Optically Pure Substances.” 1985.

Barbachyn, M. R.; Johnson, C. R.  “Optical Activation and Utilization of Compounds Containing Chiral Sulfur Centers.”  In Asymmetric Synthesis; Morrison, J. D.; Education Academic Press: New York, Vol. 4, Chapter 2. 1984.

Danishefsky, S. J.; Maring, C. J.; Barbachyn, M. R.; Segmuller, B. E.; Journal of Organic Chemistry, 49, 4564.  “An Approach to the Synthesis of Carbon-Carbon Linked Disaccharides.” 1984. 

Johnson, C. R.; Barbachyn, M. R.; Journal of the American Chemistry Society, 106, 2459.  “Sulfoximine-Directed Osmylation:  Synthesis of Enantiomerically Pure Dihydroxycycloalkanones.” 1984. 

Barbachyn, M. R.; Johnson, C. R.; Glick, M. D.; Journal of Organic Chemistry, 49, 2746.  “Synthesis and Absolute Configuration of (-)-Rothrockene, a Non-Head-to-Tail Monoterpene.” 1984. 

Johnson, C. R.; Barbachyn, M. R.; Journal of the American Chemistry Society, 104, 4290.  “β-Hydroxysulfoximine-Directed Simmons-Smith Cyclopropanations.  Synthesis of (-)- and (+)-Thujopsene.” 1982.

DeKock, R. L.; Barbachyn, M. R.; Journal of Inorganic and Nuclear Chemistry, 43, 2645.  “Electronic Structure and Molecular Topology of Boron and Aluminum Suboxides.” 1981.

DeKock, R. L.; Barbachyn, M. R.; Journal of the American Chemistry Society, 101, 6516-6519.  “Proton affinity Ionization Energy, and the Nature of Frontier Orbital Electron Density.” 1979.

Patents

Additional patent applications pending. 

Thomas, R. C; Poel, T.-J.; Barbachyn, M. R.; Gordeev, M. F.; et al. N-aryl-2-oxazolidinone-5-carboxamides and their derivatives.  U.S. 7,645,781, January 12, 2010.

Barbachyn, M. R.; Ruble, J. C.; Romero, A. G.; Thomasco, L. N.; Hurd, A. R.; et al. Tricyclic tetrahydroquinoline antibacterial agents.  U.S. 7,605,157, October 20, 2009.

Barbachyn, M. R.; Bundy, G. L.; et al. Tricyclic Tetrahydroquinoline Antibacterial Agents.  U.S. 7,208,490, April 24, 2007.

Thomas, Richard C.; Poel, Toni-jo; Barbachyn, Michael R.; Gordeev, Mikhail F.; Luehr, Gary W.; Renslo, Adam; Singh, Upinder.  U.S. 6,919,329, July 19, 2005.

Gordeev; Mikhail F.; Patel; Dinesh V.; Barbachyn; Michael R.; Gage; James R. U.S. 6,869,965, March 22, 2005.

Genin, M. J.; Barbachyn, M. R.; Hester, Jr., J. B.; Johnson, P. D.; Ciske, F. L.  U.S. 6,825,225, November 30, 2004.

Gordeev, M. F.; Patel, D. V.; Barbachyn, M. R.; Gage, J. R.  U.S. 6,689,769, February 10, 2004.

Barbachyn, M. R. A Thiazine Oxazolidinone.  U.S. 6,605,609, August 12, 2003.

Barbachyn, M. R.; Genin, M. J.; Hester, J. B., Jr.; Johnson, P. D.  Bicyclic Oxazolidinones as Antibacterial Agents.  U.S. 6,387,896, May 14, 2002.

Barbachyn, M. R.; Homa, F. L.; Monge, A.; Santiago, E.; Martinez-Irujo, J. J.; Font, M.  Polyaromatic Antiviral Compositions. U.S. 6,147,116, November 14, 2000.

Barbachyn, M. R.; Thomas, R. C.; Cleek, G. J.  Isoxazoline Derivatives Useful as Antimicrobials.  U.S. 6,093,736, July 25, 2000.

Barbachyn, M. R.; Brickner, S. J.; Hutchinson, D. K.  Spirocyclic and Bicyclic Diazinyl and Carbazinyl Oxazolidinones.  U.S. 6,090,820, July 18, 2000.

Poel, T. J.; Martin, J. P., Jr.; Barbachyn, M. R.  S-Oxide and S,S-Dioxide Tetrahydrothiopyran Phenyloxazolidinones.  U.S. 6,083,967, July 4, 2000.

Barbachyn, M. R.; Morris, J.; Wishka, D. G.; Cleek, G. J.; Thomas, R. C.  Substituted Aminophenyl Isoxazoline Derivatives Useful as Antimicrobials.  U.S. 6,069,141, May 30, 2000.

Barbachyn, M. R.; Cleek, G. J.; Thomas, R. C.  Isoxazoline Derivatives Useful as Antimicrobials.  U.S. 5,990,136, November 23, 1999.

Thomas, R. C.; Poel, T. J.; Barbachyn, M. R.  Phenyloxazolidinones Having a C-C Bond to 4-8 Membered Heterocyclic Rings.  U.S. 5,968,962, October 19, 1999.

Barbachyn, M. R.; Homa, F. L.; Monge, A.; Santiago, E.; Martinez-Irujo, J. J.; Font, M.  Polyaromatic Antiviral Compositions. U.S. 5,958,983, September 28, 1999.

Barbachyn, M. R.; Thomas, R. C.; Cleek, G. L.; Thomasco, L. M.; Gadwood, R. C. Bicyclic Oxazine and Thiazine Oxazolidinone Antibacterials.  U.S. 5,952,324, September 14, 1999.

Barbachyn, M. R.; Brickner, S. J. Substituted Heteroarylphenyloxazolidinones.  U.S. 5,929,248, July 27, 1999.

Hutchinson, D. K.; Brickner, S. J.; Barbachyn, M. R.; Taniguchi, M.; Munesada, K.; Yamada, H.  Phenyloxazolidinone Antimicrobials.  U.S. 5,883,093, March 16, 1999.

Barbachyn, M. R.; Hutchinson, D. K.; Brickner, S. J.  Substituted Oxazine and Thiazine Oxazolidinone Antimicrobials.  U.S. 5,880,118, March 9, 1999.

Pearlman, B. A.; Perrault, W. R.; Barbachyn, M. R.; Manninen, P. R.; Toops, D. S.; Houser, D. J.; Fleck, T. J.  Process to Prepare Oxazolidinones.  U.S. 5,837,870, November 17, 1998.

Barbachyn, M. R.; Brickner, S. J. Substituted Heteroarylphenyloxazolidinones.  U.S. 5,801,246, September 1, 1998.

Barbachyn, M. R.; Brickner, S. J. Substituted Heteroarylphenyloxazolidinones.  U.S. 5,756,732, May 26, 1998.

Gadwood, R. C.; Barbachyn, M. R.; Toops, D. S.; Smith, H. W.; Vaillancourt, V. A.  Azolyl Piperazinyl Phenyl Oxazolidinone Antimicrobials.  U.S. 5,736,545, April 7, 1998.

Hester, J. B.; Brickner, S. J.; Barbachyn, M. R.; Hutchinson, D. K.; Toops, D. S.  5-Amidomethyl a,b-Saturated and Unsaturated 3-Aryl Butyrolactone Antibacterial Agents.  U.S. 5,708,169, January 13, 1998.

Hutchinson, D. K.; Barbachyn, M. R.; Brickner, S. J.; Gammill, R. B.; Patel, M. V. Oxazolidinone Antimicrobials Containing Substituted Diazine Moieties.  U.S. 5,700,799, December 23, 1997.

Barbachyn, M. R.; Brickner, S. J. Substituted Aryl- and Heteroarylphenyloxazolidinones.  U.S. 5,654,435, August 5, 1997.

Barbachyn, M. R.; Brickner, S. J. Substituted Aryl- and Heteroarylphenyloxazolidinones.  U.S. 5,654,428, August 5, 1997.

Brickner, S. J.; Barbachyn, M. R.; Hutchinson, D. K.  Esters of Substituted Hydroxyacetyl Piperazine Phenyl Oxazolidinones.  U.S. 5,652,238, July 29, 1997.

Barbachyn, M. R.; Brickner, S. J. Substituted Aryl- and Heteroarylphenyloxazolidinones.  U.S. 5,565,571, October 15, 1996.

Hutchinson, D. K.; Barbachyn, M. R.; Brickner, S. J.; Gammill, R. B.; Patel, M. V. Oxazolidinone Antimicrobials Containing Substituted Diazine Moieties.  U.S. 5,547,950, August 20, 1996.

Barbachyn, M. R.  Tropone-Substituted Phenyloxazolidinone Antibacterial Agents.  U.S. 5,523,403, June 4, 1996.

Gammill, R. B.; Bisaha, S. N.; Timko, J. M.; Judge, T. M.; Barbachyn, M. R.; Kim, K. S.  Antibacterial Quinolone Compounds.  U.S. 5,385,906, January 31, 1995.

Barbachyn, M. R.  Novel N-1 Substituted b-Lactams as Antibiotics.  U.S. 5,006,650, April 9, 1991.

Barbachyn, M. R., Brickner, S. J., Thomas, R. C.  Antibiotic Sulfonylaminocarbonyl Activated b-Lactams.  U.S. 4,975,538, December 4, 1990.

Awards

  • 2007 - Pharmaceutical Research & Manufacturers of America (PhRMA) Discoverers Award 
  • 2007 - American Chemical Society National Award for Team Innovation 
  • 2003 - American Chemical Society Regional Industrial Innovation Award 
  • 2001 - Upjohn Award 
  • 2001 - Pharmacia Fellow Charter Member 
  • 1995 - Fred Kagan Lead Finding Award, The Upjohn Company 
  • 1987 - Fred Kagan Lead Finding Award, The Upjohn Company 
×

  • Course code:
  • Credits:
  • Semester:
  • Department:
Top